February 25, 2022
Our Bold Goal for the Pancreatic Cancer Survival Rate - Cassadie Moravek
Cassadie Moravek
Senior Director, Clinical Trial Portfolio and Program Management at Pancreatic Cancer Action Network
GuestPancreatic cancer is one of the deadliest forms of cancer. With a five-year survival rate of just 11%, a diagnosis has long been considered a death sentence.
However, there is hope. Cassadie Moravek, a director of clinical trial operations at the Pancreatic Cancer Action Network, joins us to explain how genetic testing and biomarkers are changing the game for patients – and elaborates on ambitious plans to increase the survival rate to 20% by 2030.
"So many people don't realize the options available to them, even though genetic testing has made huge leaps forward in the last few years."